TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03130335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMA Injection
Description: Bone marrow will be aspirated from the iliac crest and injected into the knee.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMA
Description: Bone marrow will be aspirated from the iliac crest.
Study: NCT03018990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 1 milliliter per kilogram body weight adjusted for elevated body mass index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 1 milliliter per kilogram body weight adjusted for elevated body mass index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 1 milliliter per kilogram body weight adjusted for elevated body mass index
Study: NCT01604239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shinbaro Capsule
Description: 600mg twice a day (b.i.d) oral herbal medicine
Study: NCT01257633

Intervention type: PROCEDURE
Intervention: Transoral robot-assisted tumor resection using the da Vinci robot
Description: Transoral robot-assisted tumor resection using the da Vinci robot
Study: NCT03810937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: head position
Description: head positioning in sniffing or flat position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: head position
Description: head positioning in sniffing or flat position
Study: NCT02417337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study: NCT01165047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
Study: NCT01238796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telavancin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telavancin
Description: Intravenous
Study: NCT01317849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 0.8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 500ug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10mg
Study: NCT02741895

Intervention type: BEHAVIORAL
Intervention: Fitbit monitoring
Description: Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
Study: NCT04185363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily
Study: NCT02417337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study: NCT02816970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 1 tablet contains 50 mg vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: 1 tablet contains 50 mg vildagliptin
Study: NCT03013413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography
Description: Undergo ultrasound-based elastography imaging using the Aixplorer system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Elasticity Imaging
Description: Undergo ultrasound-based elastography imaging using the Aixplorer system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Prostate Biopsy
Description: Undergo standard of care ultrasound-guided prostate biopsy
Study: NCT02663921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part A: Baseline-Week 2
Description: The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~1. Immediately after the light exposure;~2. 30 minutes after light exposure; and~3. 1 hour after light exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part B: Week 4-Week 12
Description: The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~1. Visual Clinical Assessment~2. Spectroscopy~3. Colorimetry
Study: NCT03115697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose 20 mL
Study: NCT05112068

Intervention type: OTHER
Intervention: traditional skin care method
Description: Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.

Intervention type: OTHER
Intervention: method using specialized gloves
Description: Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying.
Study: NCT04561531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3%NaCl
Description: Intervention is infusion of 3%NaCl which is defined in arms of experiment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3%NaCl
Description: Intervention is infusion of 3%NaCl which is defined in arms of experiment.
Study: NCT03080714

Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes

Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes

Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
Study: NCT01317849

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500ug
Study: NCT04599790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with lenvatinib and sintilimab
Description: Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study: NCT00884507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: 1mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: 5mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5313534
Description: 15mg po daily for 24 weeks
Study: NCT03927976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Path2Quit - culturally specific text message intervention
Description: SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
Study: NCT05126615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Description: Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Chronic Post-Surgical Pain evaluation
Description: Different questionnaires :~BPI : Brief Pain Inventory DN4

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Post-Surgical Pain evaluation
Description: Different questionnaires :~BPI : Brief Pain Inventory DN4
Study: NCT03852212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Thrust technique application
Study: NCT00693719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
Study: NCT05066893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telehealth visits
Description: intensive visits with doctor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telehealth visits
Description: intensive visits with doctor
Study: NCT00928980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Care
Description: Therapeutic dose of antidepressant medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Care
Description: Therapeutic dose of antidepressant medication
Study: NCT01232946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8mg subcutaneous qd for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide plus insulin detemir
Description: liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.
Study: NCT00734929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant + Dexamethasone
Description: Aprepitant 40 mg + Dexamethasone 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron + Dexamethasone
Description: Ondansetron 4 mg + Dexamethasone 10 mg
Study: NCT03550339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SURG
Description: bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HAES
Description: treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
Study: NCT04729127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ImPACT
Description: Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project ImPACT
Description: Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).
Study: NCT01904461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Study: NCT01238796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telavancin
Description: Intravenous
Study: NCT03866772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Tablet
Description: 50 mcg oral consumption

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Tablet
Description: 50 mcg oral consumption

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double balloon device for cervical ripening
Description: insertion for 6 hours and followed by the above mentioned protocol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double balloon device for cervical ripening
Description: insertion for 6 hours and followed by the above mentioned protocol
Study: NCT04873778

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio taping
Description: Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic taping
Description: Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
Study: NCT00003501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00098293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Zidovudine/Lamivudine
Description: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study: NCT03115697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 550 BD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Plasmapheresis 8 hrly duration
Study: NCT03884894

Intervention type: DIAGNOSTIC_TEST
Intervention: molecular assay
Description: performed with blood culture simultaneously

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood culture
Description: performed with molecular assay simultaneously
Study: NCT02465125

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: red blood cell transfusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: red blood cell transfusion
Study: NCT02442687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JKB-121: 5 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JKB-121: 10 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00849797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: 600 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trileptal®
Description: 600 mg Tablet
Study: NCT04366544

Intervention type: OTHER
Group type: OTHER
Intervention: Part A1: Survey
Description: Online

Intervention type: OTHER
Group type: OTHER
Intervention: Part A1: Survey
Description: Online

Intervention type: OTHER
Group type: OTHER
Intervention: Part A1: Survey
Description: Online

Intervention type: OTHER
Group type: OTHER
Intervention: Part A1: Survey
Description: Online

Intervention type: OTHER
Group type: OTHER
Intervention: Part A2: Sample collection
Description: Blood and Stool
Study: NCT00098293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz + Zidovudine/Lamivudine
Description: efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Description: maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study: NCT02742974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac™ and EV1000™
Description: Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
Study: NCT03666793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global care
Description: Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
Study: NCT03435315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise- behavioral approach
Description: 12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Exercise- traditional approach
Description: 12-session, 6-week traditional treadmill exercise program
Study: NCT04168138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
Study: NCT00689052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole ER

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03480516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% silver diamine fluoride solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% silver diamine fluoride solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: 5% sodium fluoride varnish

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: 5% sodium fluoride varnish
Study: NCT03511066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P27 90 mg/kg
Description: Influenza A treatment drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P27 45 mg/kg
Description: Influenza A treatment drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study: NCT05136521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl - new polymer
Description: A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl - Contramid®
Description: A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.